subscribeSubscribe
Enforcement Report - Week of July 26, 2023

Enforcement Report - Week of July 26, 2023
FDA
26 Jul 2023
Share Share
US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent

US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent
REUTERS
18 Apr 2023
Share Share
Vyne swings behind BET, seeks partner for failed eczema drug

Vyne swings behind BET, seeks partner for failed eczema drug
Nick Paul Taylor FIERCE BIOTECH
10 Mar 2023
Share Share
Drug, TASCENSO ODT , Launched to Meet the Needs of Multiple Sclerosis Patients

Drug, TASCENSO ODT , Launched to Meet the Needs of Multiple Sclerosis Patients
BUSINESSWIRE
13 Feb 2023
Share Share
Novartis takes Gilenya patent case to Supreme Court

Novartis takes Gilenya patent case to Supreme Court
FIERCE PHARMA
25 Jan 2023
Share Share
Multiple Sclerosis Patients in US Left Without Essential Patient Support Program Will Now Receive Equivalent Backing From Cycle Pharmaceuticals Following FDA’s Approval of TASCENSO ODT (fingolimod)

Multiple Sclerosis Patients in US Left Without Essential Patient Support Program Will Now Receive Equivalent Backing From Cycle Pharmaceuticals Following FDA’s Approval of TASCENSO ODT (fingolimod)
BUSINESSWIRE
17 Jan 2023
Share Share
Supreme Court rejects Novartis` request for stay in Gilenya patent battle 

Supreme Court rejects Novartis` request for stay in Gilenya patent battle 
Nicole DeFeudis ENDPTS
15 Oct 2022
Share Share
U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug

U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug
REUTERS
13 Oct 2022
Share Share
Bionpharma`s Generic Fingolimod Hydrochloride Receives Approval in the U.S.

Bionpharma`s Generic Fingolimod Hydrochloride Receives Approval in the U.S.
FDA
06 Oct 2022
Share Share
Novartis takes Gilenya fight to Supreme Court as generic competition looms

Novartis takes Gilenya fight to Supreme Court as generic competition looms
Nicole DeFeudis ENDPTS
22 Sep 2022
Share Share